TacticScaleWhat Azenta Does & How It Makes Money (AZTA)
Updated October 2026 · reflects Azenta's latest reported financials
Life sciences sample storage, management, and genomic analysis services provider. It makes money by selling sample storage equipment, tubes, and consumables, by charging for sample repository and consulting services, and by charging fees for gene sequencing, gene synthesis, and other sample analysis services.
How Azenta makes money
It makes money by selling sample storage equipment, tubes, and consumables, by charging for sample repository and consulting services, and by charging fees for gene sequencing, gene synthesis, and other sample analysis services.
What Azenta does
Azenta, Inc., formerly Brooks Automation, focuses on life sciences and is based in Burlington, Massachusetts. It helps researchers and drug developers store, manage, and analyze biological and chemical samples. It operates in the United States, China, the United Kingdom, the rest of Europe, Asia Pacific, and other markets. The company was founded in 1978 and took the Azenta name in December 2021. It has two segments. Sample Management Solutions sells automated storage systems, cryogenic systems, sample tubes, consumables, instruments, and controlled rate thawing devices, and also offers sample repository services and experiment-design consulting. Multiomics provides gene sequencing, gene synthesis, and related sample analysis services. Azenta also has a strategic partnership with Frontier Space Ltd to run scientific experiments in space.
Products & services
- Automated sample stores
- Cryogenic storage systems
- Automated sample tubes and consumables
- Controlled rate thawing devices
- Sample repository services
- Gene sequencing and gene synthesis services
What is Azenta worth?
On an owner-earnings DCF, Azenta's most-likely value is about $23 versus a recent price near $38 (38% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$12) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Avantor (AVTR) · Agilent Technologies (A) · BioLife Solutions (BLFS) · Bio-Techne (TECH)